Tony Richardson, the chief executive of Venn Life Sciences (), says the clinical research group has spotted an opportunity in its marketplace.
Richardson says he would like the group to add sites in Central and Eastern Europe and explains why Europe is “reassuringly complicated”.
The AIM-listed group has just landed a €1.4mln contract to conduct a Europe-wide phase II study for an unnamed US-based company.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE